Archimed exits clinical diagnostics company Diesse to Fremman Capital

The sale has returned 4.6 times to shareholders.

27 January 2025•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.